Long-term use of ospemifene in clinical practice for vulvo-vaginal atrophy: end results at 12 months of follow-up-Reference-Cited by-同舟云学术

Long-term use of ospemifene in clinical practice for vulvo-vaginal atrophy: end results at 12 months of follow-up

Published:2022-06-07 Issue:7 Volume:38 Page:577-582
ISSN:0951-3590
Container-title:Gynecological Endocrinology
language:en
Short-container-title:Gynecological Endocrinology

Author:

Pingarrón Santofímia Carmen¹,Lafuente González Pilar²,Guitiérrez Vélez María del Carmen²,Calvente Aguilar Virginia²,Poyo Torcal Silvia²,Terol Sánchez Pablo²,Palacios Santiago³

Affiliation:

1. Servicio de Ginecología y Oncoginecología, Universidad Europea de Madrid. Hospital Quirónsalud San José, Madrid, Spain

2. Servicio de Ginecología y Oncoginecología. Hospital Quirónsalud San José, Madrid, Spain

3. Palacios Institute of Women’s Health, Madrid, Spain

Publisher

Informa UK Limited

Subject

Obstetrics and Gynecology,Endocrinology,Endocrinology, Diabetes and Metabolism

Link

https://www.tandfonline.com/doi/pdf/10.1080/09513590.2022.2083103

Reference27 articles.

1. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women

2. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy

3. Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: A randomised, placebo-controlled, phase III trial

4. Endometrial safety

5. Continuing Medical Education: Vulvovaginal Atrophy: Current and Future Therapies (CME)

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and Serum Estradiol Levels in Hormonal Treatments for Vulvovaginal Atrophy in Breast Cancer Survivors: A Systematic Review and Meta-Analysis;Clinical Breast Cancer;2023-12

2. Hormone therapy for sexual function in perimenopausal and postmenopausal women;Cochrane Database of Systematic Reviews;2023-08-24

3. Efficacy, tolerability, and endometrial safety of ospemifene compared with current therapies for the treatment of vulvovaginal atrophy: a systematic literature review and network meta-analysis;Menopause;2023-06-27

4. Non-hormonal treatments for managing vulvovaginal atrophy/genitourinary syndrome of menopause;Climacteric;2023-05-18